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INTRODUCTION 
 
Upper gastrointestinal endoscopy is routinely performed 
everyday for a number of patients in the department of Medical 
Gastroenterology, Government Rajaji Hospital. It is generally 
considered the diagnostic method of choice in uninvestigated 
dyspepsia because it allows  identification of structural causes of 
dyspepsia and most importantly excludes carcinoma, but 
examination of all patients is hard to perform. The reason is the 
high annual incidence of dyspepsia. The issue is even more 
important in developing countries like ours with limited access to 
diagnostic services. There is no generally accepted consensus about 
the age cut off for upper GI endoscopy, because it mainly depends 
on the regional age-specific incidence of gastric cancer. 
The association of Helicobacter pylori with various 
gastrointestinal disorders has been studied in the past few years. 
The relation between peptic ulcer and H.pylori is well established 
throughout world literature. The ultra rapid urease test has been 
used in the past few years to study the presence of organism in the 
endoscopic specimen. Though there are several methods used to 
detect the organism, most of them are expensive and cumbersome 
to perform. This test provides a quicker and cheaper means to study 
the organism with a high degree of sensitivity and specificity. 
The association of H.pylori with peptic ulcer and gastric 
adenocarcinoma was suggested by its discoverer Barry Marshall. In 
1984, it was again described shortly after subsequent studies 
assessed its role in GERD and non ulcer dyspepsia. It was found to 
be one of the etiological factors for gastric adenocarcinoma and 
gastric MALTomas in 1991. It was identified as a grade I 
carcinogen in 1994 and the importance of its eradication in patients 
with a positive family history of carcinoma was stressed. Its 
association with non ulcer dyspepsia is less well understood despite 
several studies in the past. The histology of non ulcer dyspepsia has 
also not been studied in detail in the past. The few studies which 
are available indicate that there could be a role for H.pylori but has 
not been  determined with accuracy. 
 
REVIEW OF LITERATURE 
 
Upper gastrointestinal tract symptoms are common in 
patients with chronic kidney disease (CKD) who require peritoneal 
dialysis (PD) or hemodialysis (HD). Anorexia, singultus (hiccups), 
nausea, vomiting, epigastric pain, and heartburn are common 
manifestations of azotemia. Delayed gastric emptying is common 
in CKD. Although the prevalence of peptic ulcer is only 2%, which 
is not significantly different from that in the general population, 
gastritis, duodenitis, and mucosal  erosions are commonly seen.368 
Various data suggest that neither hyperacidity, hypergastrinemia, or 
H. pylori play major roles in the pathogenesis of uremic gastro-
pathy, although these data have recently been called into question.  
 
Impaired mucosal cytoprotection has been postulated but not 
proved. Also seen on esophagogastroduodenoscopy are esophagitis, 
Brunner's gland hyperplasia, gastric fold thickening, and nodular 
duodenitis (which resolves after renal transplantation) and 
angiodysplasia. GERD may be related to the absence of H. pylori 
infection, amyloidosi, and PD, which increases intra-abdominal 
pressure. In controlled studies, the incidence of gallstones in CKD 
is similar to healthy controls. 
 
It is possible that angiodysplastic lesions in the upper and 
lower gastrointestinal tract are no more common in patients with 
CKD than in the general population but are discovered more 
frequently because of their greater tendency to bleed. 
Angiodysplasia in kidney disease represent acquired lesions formed 
by repeated episodes of submucosal venous outflow obstruction 
resulting in incompetent precapillary sphincters with subsequent 
arteriovenous communication.  
 
Angiodysplastic lesions are much more likely to bleed in 
patients with CKD than in patients with normal renal function, 
perhaps because of uremic platelet dysfunction. In a series of, CKD 
patients with upper gastrointestinal hemorrhage, gastric ulcer (37%) 
and duodenal ulcer (23%) were the two most common bleeding 
lesions, but angiodysplasia of the upper gastrointestinal tract was 
the cause of bleeding in 13%. In contrast, angiodysplasia was only 
responsible for 1.3% of upper intestinal tract bleeding in control 
patients. In CKD patients with recurrent hemorrhage, 
angiodysplasia was the most frequent cause of bleeding. 
Angiodysplasia as a cause of bleeding was most closely associated 
with the duration of renal failure and the need for hemodialysis. In 
CKD, peptic lesions may be managed successfully with standard 
medical treatments in appropriate "renal" doses and angiodysplasia 
may be treated with laser, electrocoagulation, or surgery.  
 
 Small intestinal complications of CKD include ileus, 
ulceration, and nonocclusive ischemic bowel disease. Diarrhea may 
occur secondary to bacterial overgrowth related to abnormal small 
intestinal motility. In addition, exocrine pancreatic insufficiency 
has been documented in a number of hemodialysis patients. The 
cause of the condition is not known, but Patients may improve 
clinically with pancreatic enzyme replacement.   
 
Patients with CKD appear more likely to develop  colonic 
perforation from ruptured diverticula, fecalomas (secondary to the 
use of aluminum-containing antacids or barium), or cecal ulcers 
that may bleed profusely. Life-threatening hemorrhage from rectal 
ulcers has also been reported. Colonic intussusception and ileus are 
also encountered in CKD. The diarrhea experienced by some 
patients with CKD appears to be related to abnormal bile acid 
metabolism.  Ischemic colitis in patients receiving HD tends to be 
more right sided in anatomic distribution, which is associated with 
poor outcome. 
 
 
 
 
 
 
 
 
 
HELICOBACTER PYLORI 
 
After its discovery by Warren and Marshall in the year 1982 
and its association with gastritis, it has been extensively studied in 
the pathogenesis of various gastric lesions. It is a spiral gram 
negative bacterium which is motile and mainly colonizes the zone 
beneath the gastric mucus which overlies the gastric epithelial cells. 
The organism may be found in any part of the stomach but prefers 
the antrum where the parietal cells are scanty in number or absent. 
H.pylori can be demonstrated in saliva, gastric juice and dental 
plaques by the sensitive PCR technique. Oro oral and feco-oral are 
likely pathways of transmission. 
The infection is more prevalent in the developing countries 
(up to 90%) and is facilitated by conditions of overcrowding, poor 
living facilities. Low socioeconomic status and low education level 
are also known to increase infection rates. Rate of acquisition of 
infection increase with age and there is no specific gender 
predilection. There are high infection rates among smokers. 
PATHOGENESIS OF GASTRIC LESIONS 
 
Cag A gene possessing strains are common in people with 
peptic ulcer or adenocarcinoma. All HP strains possess Vac A gene 
but only 40% are toxigenic. The characteristic motility of the 
organism allows it to move rapidly through viscous mucus. Once 
the organism is safely encased in the mucus, it is able to fight the 
gastric acidity with the help of urease and converts urea into 
ammonia, which is a strong base, thus creating a cloud of acid 
neutralizing chemicals around the organism and protecting it from 
gastric acidity.  
 
Another defense that the organism has is that, the body's 
natural defenses cannot reach the bacterium in the mucus lining of 
the stomach. The immune system responds strongly to the infection 
with a host of immune cells which unfortunately cannot get through 
the gastric lining.  
 
 But they  are localized just outside the stomach lining and 
thus a vicious cytotoxic immune response ensues, producing 
gastritis and peptic ulceration. It may not be the organism itself 
which causes peptic ulcer but in fact the host response to H.pylori. 
 
Although the organism is non invasive, the bacterium 
stimulates chronic gastritis by provoking a local imflammatory 
response in the underlying epithelium due to a variety of 
cytotoxins. Once infection in the antrum is established, there is 
depletion of antral somatostatin and stimulation of gastrin release 
from G cells. Subsequent hypergastrinemia stimulates acid 
production by the parietal cells, leading to duodenal ulceration. The 
role of HP in gastric ulcer is less clear but HP probably reduces 
gastric mucosal resistance to attack from acid and pepsin. Host 
response to infection is characterized by an acute neutrophilic 
infiltrate in the acute stage followed by a chronic inflammatory cell 
infiltrate in the later stages, the Th I response predominating. 
 
The following types of chronic gastritis have been found to 
be associated with HP infection  
Type A :  atrophic in nature and have parietal cell  
   antibodies 
Type B :  no parietal cell antibodies 
Type AB :  atrophic and patchy 
 
Chronic gastritis in HP has been found to be associated with 
intestinal metaplasia and increases risk of gastric adenocarcinoma. 
HP infection has been very strongly linked to duodenal ulcer, the 
prevalence rates reaching close to 100%. Eradication of HP in DU 
gives awarding results. The most serious lesion caused by HP is 
gastric cancer. The pathogenesis is represented as follows by 
Correa's multi step hypothesis. 
H.pylori   Æ   Chronic active gastritis    Æ Atrophy 
  
     Dysplasia          Intestinal metaplasia 
 
Distal gastric cancer 
  
 
TABLE – 1     
Association of HP with various gastric disorders 
 
Chronic gastritis 50-65% 
Duodenal ulcer 95-98% 
Gastric ulcer 60-75% 
Non ulcer dyspepsia 50-60% 
Gastric adenocarcinoma six fold increase 
Gastric MAL Toma 93-98% 
 
 
 
 
 
 
 
 DIAGNOSIS OF INFECTION 
The presence of H.pylori in the stomach can be detected by 
several invasive and non invasive methods. 
Table - 2 
Invasive Non invasive 
Culture Serology 
Histology of biopsied 
specimen 
Urea breath test 
Rapid urease test 
Stool antigen test, PCR, 
urine antigen 
 
The choice of the test used depends upon the accuracy, cost, 
availability and whether the patient will be undergoing endoscopy. 
Stool antigen tests are increasingly being used as simple non 
invasive methods for H.pylori diagnosis. Serology is useful as a 
screening test but cannot differentiate between current and past 
infection. 
 
 TABLE - 3  
COMPARISONS OF VARIOUS METHODS OF DETECTION OF HP  
Feature Histo Culture RUT ELISA UBT SAT PCR
Sensitivity (%) 90 86 88-92 90-100 95-100 91 93-96
Specificity (%) 88 100 92-100 91-100 95-100 93 100 
Invasive + + + - - - - 
Expensive + +  - - - + 
Results within 24 hrs - - + - + + + I
Can Confirm 
eradication - - - - + - + 
Accuracy affected by 
recent treatment with 
PPI / antibiotics 
+ + + - + - - 
 
Histo   -  Histology,  
+= Yes,  -  = No,    PCR = polymerase chain reaction,  
RUT = rapid urease test,  URT = urea breath test,  
SAT = stool antigen test,       ELISA=enzyme linked  
     immunosorbent assay  
 
 MANAGEMENT OF DYSPEPSIA AND H.PYLORI 
INFECTION 
 
The clinician evaluating a patient with dyspeptic symptoms 
should recognize the limitations of history taking and physical 
examination in this setting. The principal utility of the clinical 
history and physical examination is to 
(1) Identify patients with GERD and NSAID- induced dyspepsia  
(2) Identify patients with alarm symptoms who may require early 
investigation. 
Patients who have typical symptoms of reflux disease should 
be managed as having GERD. Patients whose symptoms are 
predominantly related to bowel function may have IBS and should 
be treated appropriately. 
Alarm features are used to try and identify patients who need 
early investigation with endoscopy. The negative predictive value 
was always >97% in various trials, reflecting the fact that upper 
gastrointestinal malignancy was a rare diagnosis.  
There are 5 initial approaches to the management of dyspepsia: 
(1) Empirical acid suppression; 
(2) A non-invasive test for H pylori, with a urea breath test, stool 
antigen test, or serology, and reserving endoscopy for positive 
cases; 
(3) A noninvasive test for H pylori and eradication therapy for 
positive cases;  
4) Empirical H pylori eradication therapy without testing;  
5) Early endoscopy.  
 
PATIENTS WITH DYSPEPSIA AND ALARM SYMPTOMS 
Due to the small but clear-cut increase in the risk of upper 
gastrointestinal malignancy, new-onset alarm symptoms or new 
onset of symptoms after the age of 55 years should prompt early 
endoscopy. This cutoff was chosen because the risk of malignancy 
in most populations is < 10 per 100,000 below the age of 55 years. 
The probability of detecting an early gastric cancer is therefore very 
low below this age. 
 
PATIENTS WITH DYSPEPSIA AND NO ALARM SYMPTOMS 
The optimal management strategy for the patient who 
presents with new onset dyspepsia and no alarm features has been 
dominated by testing for H pylori and treating all positive cases 
empirically with antibacterial therapy. However, there are other 
choices, including no testing but empirical medical therapy (e.g., an 
anti secretory agent) with any subsequent investigation reserved for 
failures or immediate evaluation by upper endoscopy in all cases 
and targeting therapy based on the results.  
In primary care, empirical anti secretory therapy remains 
popular. Only a minority of patients with dyspepsia has peptic 
ulcers, and even fewer have cancer. Therefore, in 1985, the 
American College of Physicians recommended, based on a 
literature review of outcomes and cost, that antisecretory medical 
therapy is preferable for patients without obvious organic disease 
who are younger than 45 years of age. The American College of 
Physicians further suggested that endoscopy (rather than a barium 
series) should be reserved for patients who have little or no 
response to therapy after 7-10 days or for patients whose symptoms 
have not resolved after 6-8 weeks. However, whether this age 
threshold is still applicable and the utility of empirical therapy now 
continue to be debated, especially in terms of continuing such 
treatment on a long-term basis in those with undiagnosed H pylori 
infection. 
The 3 strategies that have undergone intense evaluation are 
empirical acid suppression, H pylori test and treat, and early 
endoscopy. Preliminary data suggest that H pylori test and treat is 
more cost-effective than empirical PPI therapy in patients with 
dyspepsia. As a strategy, the efficacy of H pylori test and treat will 
vary according to whether the test is performed in primary or 
secondary care and the prevalence of infection in the population. 
“Cure" is to be offered to the patients who are infected and an 
alternate approach for those who test negative.  
 
 
 
 
 
THE MANAGEMENT OF DOCUMENTED NON 
ULCER / FUNCTIONAL DYSPEPSIA 
1. Initial PPI therapy 
2. Acid suppression, 
3. Prokinetic therapy, 
4. H pylori eradication therapy, and 
5. Psychological therapies. 
Overall, the only therapies that have established efficacy in 
functional dyspepsia are H pylori eradication and PPI therapy. 
H.pylori   eradication is the most cost-effective approach in patients 
who are positive because this treatment is only given once for a 
long-term effect. In H pylori-negative patients with functional 
dyspepsia and those who fail to respond to eradication therapy, a 
one month course of PPI therapy may be warranted. 
 
The association between H.pylori and the non ulcer dyspepsia 
has been analysed for many years and various studies have tried to 
prove the association so that these patients can be subjected to 
eradication therapy. But definite evidence is lacking. A study 
performed in Germany by Bajorsky et al concluded that HP-
infection per se contributes to dyspepsia. 85% HP positive 
dyspeptic patients improved after HP-eradication, when other 
potential. organic causes for dyspepsia had been ruled out. 
However, many patients did not completely recover but the 
symptoms only partly decreased which parallels the persistence of 
part of the inflammatory infiltration in the gastric mucosa. This 
emphasizes the importance of HP-gastritis as an organic disease 
causing dyspeptic symptoms.  
The first national workshop on H.pylori was held in Mumbai 
in the  year 1997 and the significant conclusions were as follows  
1.  The prevalence of H.pylori infection in healthy or 
asymptomatic persons in India varied from 31-84 %. 
2.  Prevalence mainly depends on the age, socioeconomic status, 
housing, sanitation and methods used for diagnosis.  
3.  Age related prevalence studies show that in India, infection 
occurs at an earlier age than in the west.  
4.  The frequency of H.pylori in non ulcer dyspepsia varies from      
60-85% and no correlation was found between the degree of 
gastric inflammation and symptoms of non ulcer dyspepsia.  
5.  There is no large study on the histological picture of the 
gastric mucosa  and its correlation to symptom response. 
6.   Invasive techniques have been the preferred mode of 
diagnosis of H.pylori in India; of these tests rapid urease test 
has been most popular, both the commercially available kits and 
the in house developed ones. 
Anitha Kamath et al compared the sensitivity and specificity 
of a commercially available urease test and an in house prepared 
urease test using histology as the gold standard. The inhouse urease 
test was cheap and more sensitive than the commercially available 
helicocheck kit. 
Thayumanavan L et al, Madurai studied the prevalence of 
H.pylori in gastroduodenal diseases during routine upper 
gastrointestinal endoscopies at Madurai and concluded that the 
organism is widely prevalent in southern parts of Tamil Nadu, the 
rapid urease test is cheap, simple and useful for detecting the 
organism, and the prevalence of infection was nearly as high in non 
ulcer dyspeptics (66%) as those with DU (86%). 
In the research setting, culture should be included in the 
protocol for confirming eradication, till the urea breath test is 
widely available. Serology is ideal for epidemiological studies. 
Warren Marshall observation proved that greater than 90% of 
DU patients were infected compared to 40% of controls. 
 
Four endoscopic surveys showed H.pylori infection in 43-
79% of NUD patients. These numbers were well above control in 
three of these surveys. At least 50% of infected persons had no 
symptoms. Some have found that infected patients are likely to 
have reflux like or ulcer like symptoms.  
 
The EUROGAST study group showed a positive correlation 
between the prevalence of gastric cancer and H.pylori in different 
parts of the world. The correlation was convincing and statistically 
significant. PC Jain et al studied the presence of H.pylori in patients 
with upper gastrointestinal symptoms using the rapid urease test 
and found significant prevalence of the organism in both ulcer and 
non ulcer dyspepsia.  
 There have been very few studies on the histopathological 
aspects of non ulcer dyspepsia and its relation to H.pylori. One 
study done in Nigeria found that significant mucosal lesions were 
found in patients who were infected with H.pylori despite normal 
endoscopy. Studies from India are lacking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ERADICATION OF HELICOBACTER PYLORI 
 
 All patients suffering from gastric or duodenal ulcers 
who are infected with H.pylori should be treated with 
antimicrobials regardless of whether they are suffering from the 
initial presentation of the disease or from recurrence. Drugs known 
to cause dyspepsia should be discontinued wherever possible. 
However, the issue of eradicating H.pylori in non ulcer dyspepsia 
remains controversial. Recent studies suggest that H.pylori should 
be eradicated even in non ulcer dyspepsia.  H. pylori eradication is 
defined as negative test for H.pylori atleast 28 days after therapy. 
 
FACTORS WHICH MODIFY TREATMENT 
1.  Bismuth and PPIs specifically inhibit the bacterial enzyme 
urease so that urease based tests might fail to detect residual 
infection or recurrence. 
2.  H.pylori tends to move to the proximal stomach during 
suppression of acid secretion. So biopsy based tests become 
inaccurate 
3.  C13 and C14 urea breath tests are most accurate because they 
sample the whole stomach and so regarded as gold standard 
to confirm eradication. 
4.  Serology is not useful to confirm eradication as it takes at 
least 6 months for the antibody titer to fall significantly 
5.  Dual therapy with a two week combination of omeprazole or 
ranitidine or bismuth citrate and either amoxicillin or 
clarithromycin eradicated H.pylori in 50-80%. In triple 
therapy, eradication may be around 50-70%. One week, twice 
daily PPI based triple therapy eradicates in about 90%. 
Second line regimens include seven days treatment with 
omeprazole and thrice daily amoxicillin and metronidazole or 
a PPI based regimen. 
 
TABLE 4  
TRIPLE REGIMENS WITH AMOXICILLIN AND 
METRONIDAZOLE 
 REGIMEN 1 REGIMEN 2 REGIMEN 3 
Drug 
Omeprazole+ Ranitidine+ Bismuth+tetracycline/ 
amoxicillin+ amoxicillin+ amoxicillin+ 
metronidazole metronidazole metronidazole 
Dose 
(daily) 
40mg once+ 300mg once+ 120mg 4 times+ 
500mg thrice+ 750mg thrice+ 500mg 4 times+ 
400mg thrice 500mg thrice 200-400mg 4 times 
Duration 7 days 12 days 2 weeks 
Efficacy 95% 90% 60-90% 
Side 
effects 
Diarrhea, nausea   
 
These standard triple regimens have been replaced by shorter 
regimens which contain amoxicillin or clarithromycin along with a 
proton pump inhibitor. These regimens are equally effective in 
eradicating the organism. 
TABLE 5 LOW DOSE TRIPLE THERAPY 
 REGIMEN 1 REGIMEN 2 
Drugs 
PPI+ Clarithromycin+ 
PPI + Amoxicillin+ 
I  
 Metronidazole Clarithromycin 
Dose( daily) I Once/twice daily+ Twice + 
 250mg twice+ 1 gm twice+ 
 400mg twice 250-500 mg twice 
Duration 7 days  
Efficacy 90% 90.% 
Side effects 
Uncommon: diarrhea, nausea with 
metronidazole 
 
QUADRUPLE THERAPY 
PPI (once/twice daily), colloid bismuth sub citrate (120mg 
four times daily), tetracyc1ine (500 mg four times daily), 
metronidazole (400-500mg 3-4 times daily) 
Duration of therapy :  seven days 
Efficacy   :  85-95% 
Side effects   :  diarrhea, nausea 
 SEQUENTIAL THERAPY 
Day 1-5 
Proton pump inhibitors twice a day 
Amoxicillin one gram twice a day 
Day 6-10 
Proton pump inhibitors twice a day 
Clarithromycin 500 mg twice a day 
Tinidazole 500 mg twice a day. 
 
Sequential therapy gives an eradication rate of around 98%. 
The sequential therapy gave a higher eradication rate than the 
conventional triple therapy and it has been suggested that it should 
be made the standard eradication therapy for H.pylori. 
 
 
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
 
1. To study the prevalence of H. Pylori in CRF patients. 
2. To study the endoscopic findings of CRF patients and 
correlate with their dyspeptic symptoms. 
3. To study the histopathology of Antral mucosa and their 
relation to dyspepsia and H. Pylori. 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Study Group : 
 The study was conducted on outpatients, inpatients visiting 
medicine department and Nephrology department.  Approval from 
the ethical committee was obtained.  The study was a cross 
sectional study conducted for a period of one year between 
November 2009 to October 2010. 
Inclusion Criteria : 
1. Patients aged   >  18 years 
2. Elevated renal parameters  >  3 months 
3. USG abdomen showing B/L contracted kidneys 
4. Anemia 
5. Dyspeptic symptoms for  > 3 months duration including 
 1. Loss of appetite 
 2. Nausea / vomiting 
 3. Epigastric discomfort / pain 
 4. Abdominal fullness / bloating 
 5. Early sateity 
 6. Loss of taste 
 7. Abnormal taste in mouth 
 8. Ammoniacal mouth smell 
 9. Oral ulcers 
 10. Weight loss 
Exclusion Criteria : 
1. Intake of NSAIDS for past 15 days 
2. Acute gastro intestinal bleed 
3. Severe systemic illness 
4. Coronary artery disease / CCF 
5. Patients refusing endoscopy 
METHODS : 
 A total number of 50 CRF patients were studied as per 
inclusion and exclusion criteria. 
 A detailed history was elicited from the patient about the 
dyspeptic symptoms and duration of symptoms.  The symptoms are 
classified under 10 sub headings and scoring was done. 
 Each symptom was given minimum score of 0 and maximum 
score of 3.  Total symptoms scoring can be upto 30.  History about 
other systemic illness and drug intake in the past was elicited. 
 Personal history, regarding Smoking, alcohol intake and 
Betalnut chewing was taken. 
 Each patient is examined for any epigastric tenderness or 
mass abdomen. 
 Their, Recent investigations were noted.  Eg. Hb%, Urea, 
Creatinine, Electrolytes, Urine analysis, USG Abdomen. 
 A detailed informed consent was obtained from the patients 
undergoing UGI endoscopy. 
 All patients were advised overnight fasting and OGD was 
performed on empty stomach in the next morning. 
 OGD was performed with flexible fibreoptic endoscope and 
the mucosa of stomach and pylorus was analysed for any lesion. 
 Scope was passed upto II part of duodenum to findout any 
pathology.  Then biopsy was taken from antral mucosa for 
histopathology. An additional sample was taken from antral 
mucosa for the tissue ultra rapid urease reaction. 
 After sterilization the scope and biopsy forceps were washed 
with sterile distilled water.  So that no error occurred in the test due 
to changes in pH. 
THE ULTRA RAPID UREASE TEST 
 
This test is a modification of the standard ureas_ test so 
that a positive result is available almost immediately. The basic 
principle behind the test is that H.pylori produces large 
quantities of urease which rapidly hydrolyses urea to ammonia. 
The urea in the test solution is hydrolysed to ammonia by the 
preformed urease present in the H.pylori positive antral biopsy 
specimen. 
The color of the solution changes from yellow to pink 
due to the change in  pH of the solution. The test solution 
consists of O.5ml of freshly prepared 1 % urea  in sterile 
distilled water to which is added two drops of 1 % phenol red 
as a pH indicator in clean capped bottles. 
 
PROCEDURE AND RESULTS 
 
A single antral mucosal biopsy was taken within five 
centimeters of the pylorus and the specimen was placed 
immediately within the test solution and remained undisturbed. 
H.pylori positive specimens changed the color of the solution 
from yellow to pink and the results were read within one 
minute. Negative test specimens were observed for 12 hours 
stored in a refrigerator. Though the intensity and velocity of 
colour change varied with patients, those who tested positive 
developed a faint pink color change around the biopsy 
specimen immediately. The whole solution changed to pink 
color immediately in some,  whereas in others a faint pink 
color developed over a period of time. Bacterial load is said to 
be the factor affecting velocity and intensity of color change. 
Solutions without H.pylori remained yellow throughout. 
 
MERITS AND DEMERITS 
 
Various studies have compared the diagnostic accuracy of 
the RUT with all other diagnostic modalities. The test has been 
shown to have a sensitivity and specificity of 90% and 100% 
respectively. The test does not give false positive results unlike 
the conventional urease test in which contaminants like Proteus 
and Pseudomonas may give a positive result with prolonged 
incubation. The rapidity of the test is said to be due to the urea 
in water solution which is unbuffered like the Christenson's 
urea broth. The test solution is very inexpensive and easy to 
prepare. The endoscopist detects the infection even before the 
instrument is withdrawn. Treatment can be instituted at once 
and the outpatient reviews can be reduced. 
The main disadvantage is that the procedure is invasive 
requiring endoscopy and biopsy. Though mostly colonization 
of bacteria in the gastric mucosa is concentrated at the antrum, 
the distribution may be patchy and biopsy from multiple sites is 
said to further increase the sensitivity of the test. This 
procedure cannot be used for screening a general population 
where a serum based test like ELISA is more practical. 
Biopsy specimens from the body, fundus and antrum 
were analysed for histopathological changes after staining, with 
routine hematoxylin and eosin. 
 
The information collected regarding all the selected cases 
were recorded in a Master Chart. Data analysis was done with 
the help of computer using SPSS Statistics Software version 
17.0.  Using this software, frequencies, percentages, means, 
standard deviations, Pearson chi square and 'p' values were 
calculated. A 'p' value less than 0.05 is taken to denote 
significant relationship. 
   
 
 
 
 
 
 
 
 
 
 
 RESULT ANALYSIS OF OBSERVED DATA 
 
 Majority of patients were from in and around Madurai.  The 
age of the patients ranged from 26 to 70 years.   
 Among the 50 patients, 38 were males and 12 were females. 
Mean age of the study population 51.08 + 10.02 
Table  1   :  Age Distribution 
           
   Mean age =  51.08 + 10.02   
P = 0.071  Not significant 
   RUT  
   Negative Positive Total 
Age 
(Binned) 
26 - 40 Count 7 0 7 
% within Age 
(Binned) 
100.0% .0% 100.0%
41 - 55 Count 17 12 29 
% within Age 
(Binned) 
58.6% 41.4% 100.0%
56 - 70 Count 11 3 14 
% within Age 
(Binned) 
78.6% 21.4% 100.0%
 Total Count 35 15 50 
% within Age 
(Binned)
70.0% 30.0% 100.0%
Symptomatology : 
 Gastro intestinal symptoms were analysed under 10 headings 
such as  
1. Loss of appetite 
2. Nausea / vomiting 
3. Epigastric Discomfort / Pain 
4. Abdomen – Fullness / Bloating 
5. Early sateity 
6. Loss of taste 
7. Abnormal taste in mouth 
8. Ammoniacal mouth smell 
9. Oral ulcers 
10.Weight loss 
Each symptom was given a score of 0 to 3. 
 0 - No symptoms 
 1 - Symptoms recalled on direct questioning 
 2 - Symptoms present but not impairing activities 
 3 - Symptoms interfering with daily work and life. 
 
Symptoms scores were added for each patient giving a 
possible score ranging from 0 -30.  If patient had less than 10 
scores he was graded as mild, 11-20 – moderate and > 20 severe 
dyspepsia. 
 
Table – 2  Symptoms Score 
   RUT  
   Negative Positive Total
Symptom Score 
(Binned) 
0 - 10 Count 19 11 30
% within SymScore 
(Binned) 
63.3% 36.7% 100.0%
11 - 20 Count 16 4 20 
% within SymScore 
(Binned) 
80.0% 20.0% 100.0%
 Total Count 35 15 50 
% within SymScore 
(Binned)
70.0% 30.0% 100.0%
 
P = 0.208  -  Not significant 
30 patients had mild dyspeptic symptoms.  20 patients 
had moderate dyspeptic symptoms.  36.7% of mild dyspeptic 
category and 20% of moderate dyspeptic category had H.pylori 
positivity.  
 
 Table –3  Symptoms Analysis 
 
Symptoms No.of cases 
Loss of appetite 48 
Nausea / vomiting 43 
Epigastric discomfort 47 
Abdominal fullness 42 
Early satiety 40 
Loss of taste 31 
Abnormal taste 18 
Ammoniacal mouth smell 18 
Oral ulcer 16 
Weight loss 39 
 
 Most frequent symptoms among CRF patients were loss 
of appetite, nausea/vomiting, epigastric discomfort. 
  
Table :  4    Sex Distribution 
 
 
Out of 50 CRF patients 38 were males, and 12 were females.  
34.3% in males and 16.7% in females are H.pylori positive. 
 
 
 
 
 
 
   RUT  
   Negative Positive Total 
Sex Female Count 10 2 12 
% within 
Sex 
83.3% 16.7% 100.0% 
Male Count 25 13 38 
% within 
Sex 
65.8% 34.2% 100.0% 
 Total Count 35 15 50 
% within 
Sex 
70.0% 30.0% 100.0% 
  
Table :  5 
  Alcohol 
 
 
 
 
 
 
 
P 0.558  -  Not significant 
Out of 50 patients, 33 do not consume alcohol, 17 consume 
alcohol. H.pylori positivity in alcoholic is 35.3%.  Non alcoholic is 
27.3%. 
 
 
 
 
   RUT  
   Negative Positive Total 
Alcoho
l 
No Count 24 9 33 
% within 
Alcohol 
72.7% 27.3% 100.0% 
Yes Count 11 6 17 
% within 
Alcohol 
64.7% 35.3% 100.0% 
 Total Count 35 15 50 
% within 
Alcohol 
70.0% 30.0% 100.0% 
  
Table – 6   :   SMOKING 
 
 
P =  0.496  -  Not significant 
 Among the 50 CRF patients, 23 are smokers, 27 are non 
smokers.  H.pylori positivity in smokers is 34.8% and non smokers 
is 25.9%.   
 
 
 
 
   RUT  
   Negative Positive Total 
Smoking No Count 20 7 27 
% within 
Smoking 
74.1% 25.9% 100.0% 
Yes Count 15 8 23 
% within 
Smoking
65.2% 34.8% 100.0% 
 Total Count 35 15 50 
% within 
Smoking 
70.0% 30.0% 100.0% 
  
Table -7   UGI scopy 
 
P = 0.529  -  Not significant 
 Among the 50 CRF patients, 48 had normal endoscopy, 2 had 
abnormal endoscopy with findings of duodenal ulcer in one patient 
and Gastritis in one patient.  
29.2% of normal endoscopy is positive for H.pylori. 50% of  
abnormal endoscopy is positive for H.pylori.   
 
 
   RUT  
   Negative Positive Total 
UGI_Sco
py 
Normal Count 34 14 48
% within 
UGI_Scopy
70.8% 29.2% 100.0%
Abnorm
al 
Count 1 1 2
% within 
UGI_Scopy 
50.0% 50.0% 100.0%
 Total Count 35 15 50
% within 
UGI_Scopy 
70.0% 30.0% 100.0%
  
Table – 8   Biopsy  
 
   RUT  
   Negative Positive Total 
Biopsy Normal Count 32 12 44 
% within 
Biopsy 
72.7% 27.3% 100.0% 
Abnorm
al 
Count 3 3 6 
% within 
Biopsy
50.0% 50.0% 100.0% 
 Total Count 35 15 50 
% within 
Biopsy 
70.0% 30.0% 100.0% 
 
P = 0.254  Not significant 
 Out of 50 specimens, 44 showed normal gastric mucosa.  
6 had abnormal findings. 
 Lymphocytic infiltration in laminapropria  =   5 
 Inflammatory cells in submucosa    = 1 
  
 
  
 
Table –9    GFR 
   
RUT  
   Negative Positive Total 
GFR 
(Binned) 
<= 15.00 Count 8 4 12 
% within GFR 
(Binned) 
66.7% 33.3% 100.0%
15.00 – 
29.00 
Count 23 11 34 
% within GFR 
(Binned) 
67.6% 32.4% 100.0%
30.00 - 
59.00 
Count 4 0 4 
% within GFR 
(Binned) 
100.0% .0% 100.0%
 Total Count 35 15 50 
% within GFR 
(Binned) 
70.0% 30.0% 100.0%
 
P = 0.393  - Not significant 
 
 
 
 
 DISCUSSION 
 
 Majority of the patients were from in and around 
Madurai. 
Age of patients ranged from 26-70 years.  Out of 50 patients 
with CRF Æ 38 were males and 12 were females.  Out of them 
30% were positive for H.pylori which goes well with the world 
statistics of H.pylori prevalence in general asymptomatic  
population.   
 V. Misra et 
al study, 
Allahabad 
Saudi 
Arabian 
study 
Croatia 
study 
Our study 
H.pylori 
prevalence 
in CRF 
 
35.2% 
 
42% 
 
45% 
 
30% 
 
 In a study conducted by Kerari EM et al at Nairobi, 
Kenya they have analysed the endoscopic findings and 
H.pylori prevalence in CRF patients with dyspepsia.  They 
found that there is no statistical difference between the 
prevalence of H.pylori in CRF patients and controls. 
Symptomatology : 
 In our patients mild to moderate dyspepsia is 
encountered. 60% had mild dyspeptic symptoms with symptom 
score 0-10 and  40% had moderate dyspeptic symptoms with 
symptom score   10-20  
63.3% of the mild dyspeptic category are negative for 
H.pylori and 36.7% of the mild dyspeptic category are positive 
for H.pylori. 
 80% of the moderate dyspeptic category are negative for 
H.pylori and 20% of the same category are positive for 
H.pylori. 
 Again we find that severity of dyspeptic symptoms have 
no correlation with the H.pylori positivity. 
 In a study conducted by V. Misra et al in Allahabad – the 
conclusion was that the patients with CRF have significant 
UGI symptoms which mainly occur due to metabolic changes 
in response to high urea concentrations in gastric juice and are 
not related to H.pylori infection. 
 Another study in Italy done by Nardone G et al showed 
clearly that Uremic patients with H.pylori positivity show low 
symptoms score and high frequency of peptic lesions. 
 Ammonia generated by the action of urease producing 
organism(s) or urea is generally held responsible for gastro 
intestinal symptoms in Uremia. However little information is 
available on the exact organism(s) available. 
 It is concluded that H.pylori present in the gastroduodenal 
mucosa of patients with renal failure does not appear to play 
significant role in severity of dyspeptic symptoms in uremic 
patients. 
 
 
UGI scopy and H.pylori : 
 UGI scopy was normal in 96% of patients and only in 4% 
it was abnormal 2% antral gastritis and 2% duodenal ulcer in 
2nd part of duodenum. 
 Among those with normal endoscopy 29.2% have 
H.pylori positive and 70.8% have H.pylori negative. 
 Among those with abnormal endoscopy 50% positive for 
H.pylori and 50% negative for H.pylori. 
 Similar study was conducted in Kuwait in 77 patients 
with CRF a prospective study.  In this the result was that there 
is no direct correlation between UGI scopy, H.pylori positivity 
and dyspeptic symptoms. 
 Normal Scopy Abnormal Scopy 
 Kuwait 
study 
Our study Kuwait 
study 
Our study 
H.Pylori 
Positive 
46 % 29.2% 54% 50% 
H.pylori 
negative 
54% 70.8% 46% 50% 
 Biopsy & Histopathology : 
 Lymphocytic infiltration in the Lamina propria and  
inflammatory cells in the submucosa was found in 6 patients. 
 3 of them were H.pylori positive and 3 were negative.  
However no lymphoid follicles are found in any of the 
specimens which is pathognomonic of H.pylori infections. 
GFR  and  H.pylori positivity 
 Patients with GFR < 15 ml / min are 12 in no out of them 
33.33% are positive for HP. 
 Patients with GFR 15 to 29 ml  Æ 34 in no. and out of 
them  Æ 4% are positive. 
 Patients with GFR 30 -  59 ml Æ 4 in no.  out of them 0% 
positive.   
 
 
 
 
  
 
 
CONCLUSION 
  
1. Prevalence of H.pylori in CRF patients is very much 
similar to non CRF patients. 
2. Severity of dyspeptic symptoms do not correlate with 
H.pylori postivity in CRF patients. 
3. Endoscopic findings do not have any relation to 
H.pylori positivity in CRF patients. 
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ABBREVIATIONS 
UGI Upper Gastro intestinal 
HP Helicobacter pylori 
H. Pylori Helicobacter pylori 
OGD Oesophago gastro duodenoscopy 
PPI Proton pump inhibitor 
PCR Polymerase chain reaction 
RUT Rapid urease test 
Th T. Helper 
CRF Chronic renal failure 
USG Ultrasonogram 
CKD Chronic kidney disease 
GFR Glomerular filteration rate 
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1.  97925 F 50 - - 14 8 - 169 4.6 12.93 +++ N - Normal 
2.  103050 F 63 - - 8 9 + 168 9.9 6.48 loaded N - Normal 
3.  104725 F 45 - - 13 6.2 + 279 8.9 8 +++ N - Normal 
4.  063241 F 60 - - 13 7.8 - 53 1.5 31.11 ++ N - Normal 
5.  062128 F 55 - - 12 8 - 56 2.1 25.29 ++ Antral 
Gastritis  
+ Focal Collection of 
Lymphocytes  
6.  43291 F 55 - - 12 8.8 - 60 2.2 26.83 ++ N - Normal 
7.  21454 F 42 - - 9 9 - 88 4.2 17.82 ++ N + Lamina propria 
inflammatory cells  
8.  21440 M 50 + + 8 7.5 - 84 4.8 14.84 - N - Normal 
9.  21438 M 41 - - 13 8.8 - 68 3.9 22.91 - N + Normal 
10.  21443 M 53 + + 9 9 - 68 4.2 17.83 - N + Normal 
11.  023501 M 43 - - 7 8 - 120 6 11.22 - N + Normal 
12.  045624 M 26 - - 10 9.6 - 147 4.5 16.53 - N - Normal 
13.  043216 M 45 + + 7 7.8 - 111 4.5 14.66 ++ Duodenal 
ulcer 
- Normal 
14.  39109 M 33 + + 8 8.6 - 48 1.9 46.92 + N - Normal 
15.  59745 M 50 + + 9 9 - 131 3.4 20.22 ++ N - Normal 
16.  82421 M 43 - - 9 8 - 143 3.9 21.41 ++ N + Normal 
17.  62814 M 50 - - 6 9.8 - 100 3.8 21.71 + N - Normal 
18.  102920 M 52 - + 7 8.6 + 144 3.4 22.28 ++ N + Normal 
19.  100721 M 60 + + 8 7.6 - 53 2.4 32.4 + N - Normal 
20.  009200 M 50 - - 10 6.8 - 106 3.9 21.79 - N + Normal 
21.  80003 M 55 - - 10 5 - 80 3.2 21.39 - N - Normal 
22.  7314 M 55 + + 3 12.4 - 115 4.3 18.47 - N - Normal 
23.  32891 M 54 + + 7 8.6 - 78 3.2 22.39 - N + Normal 
24.  23521 M 61 - - 3 9.2 + 88 2.8 21.55 - N - Normal 
25.  63214 M 55 - + 8 8.2 - 62 2.4 33.44 - N - Normal 
26.  23891 M 55 + + 8 6.8 - 82 4.1 17.27 - N + Normal 
27.  36381 M 62 + + 6 9 - 111 4.8 13.09 - N + Normal 
28.  63241 M 60 + + 6 10.2 + 66 2.4 26.85 - N - Normal 
29.  96388 M 28 - - 4 6 - 72 3.4 22.87 - N - Normal 
30.  238601 M 48 + + 6 6 - 108 6.5 12.18 - N + Normal 
31.  263821 M 52 - - 5 9 - 98 2.4 29.53 - N - Normal 
32.  238060  M 46 - + 8 9 - 80 4.2 18.65 - N - Limphocytic 
Infiltration 
33.  64290 M 68 - + 6 8.6 - 56 4.8 12.5 ++ N + Chronic 
Inflammatory cells 
34.  23841 M 60 - - 7 9 + 94 3.8 4 ++ N - Normal 
35.  285392 M 58 + + 10 8.5 - 82 2.8 23.59 ++ N - Normal 
36.  7281 F 55 - - 12 6.8 - 86 3.8 21.72 - N - Limphocytic 
Infiltration 
37.  73120 M 55 + + 12 9.5 + 64 4.2 16.3 - N + Normal 
38.  61230 M 60 - - 10 8 - 80 4.1 16.26 - N - Limphocytic 
Infiltration 
39.  84291 M 65 - - 14 9 - 78 2.8 20.46 - N + Normal  
40.  299856 F 35 - - 12 8.9 - 80 3.2 22.78 - N - Normal  
41.  67321 M 42 - + 11 9.2 - 68 2.8 28.19 - N - Normal  
42.  42525 M 38 - + 14 8 + 88 3 28.83 ++ N - Normal  
43.  24261 M 70 - - 14 8.2 - 40 1.8 28.08 - N - Normal  
44.  55165 M 60 - + 15 8 - 68 4 16.11 - N - Normal  
45.  054209 M 35 + - 16 6.8 - 82 2.8 22.19 - N - Normal  
46.  056150 M 60 + + 14 7 - 56 3.8 17.51 - N - Normal  
47.  059822 F 51 - - 19 8 - 82 6.2 10.36 - N - Normal  
48.  069487 M 55 + + 13 8 + 80 4.2 16 - N - Normal  
49.  82639 F 35 - - 16 6.8 - 98 5.2 13.46 - N - Normal  
50.  760097 F 55 - - 14 7 - 86 4.6 15.09 - N - Normal  
 
